{"filing":{"accession_number":"0001213900-26-063235","cik":"0001839140","ticker":"RVRC","company_name":"Revium Rx.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"ea0292932-8k_revium.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839140/000121390026063235/ea0292932-8k_revium.htm"},"events":[{"id":7855,"run_id":6892,"accession_number":"0001213900-26-063235","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses both a CFO departure (Arie Gordashnikov) and an appointment (Igor Bluvstein) on the same date. The principal action emphasized is the appointment of Bluvstein as CFO, with detailed background on his 17+ years of financial leadership experience across multiple public companies (Argent BioPharma, G Medical Innovations, etc.). While a departure also occurred, the appointment is the forward-looking material event that would affect investor assessment of the company's financial leadership and governance.","company_name":"Revium Rx.","ticker":"RVRC","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3229,"accession_number":"0001213900-26-063235","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a CFO departure (Arie Gordashnikov) and an appointment (Igor Bluvstein) on the same date. The principal action emphasized is the appointment of Bluvstein as CFO, with detailed background on his 17+ years of financial leadership experience across multiple public companies (Argent BioPharma, G Medical Innovations, etc.). While a departure also occurred, the appointment is the forward-looking material event that would affect investor assessment of the company's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:59.531643+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3229,"accession_number":"0001213900-26-063235","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a CFO departure (Arie Gordashnikov) and an appointment (Igor Bluvstein) on the same date. The principal action emphasized is the appointment of Bluvstein as CFO, with detailed background on his 17+ years of financial leadership experience across multiple public companies (Argent BioPharma, G Medical Innovations, etc.). While a departure also occurred, the appointment is the forward-looking material event that would affect investor assessment of the company's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:59.531643+00:00","company_name":"Revium Rx.","ticker":"RVRC","filing_date":"2026-06-01"}]}